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969-31 Influenceof LowHDL-ConProgressionof CAD
end Response to Fluvastatin Therapy
C.M. Ballanfyne, J.A. Herd, M.S. West, H.J. Pownall, J.A. Farmer,
P.H.Jones, A.M. Gotto, Jr.. Baylor College of Medicine, Houston, TX, USA
Decreased HDL-C and mildly elevated LDL-C are common in pts with CAD.
We examined the influence of low HDL-C on QCA-defined CAD progression
using date from the 2.5-year Lipoprotein and Coronary Atherosclerosis Study
(LCAS). LCAS randomized 429 men and women with angiographic evidence
of CAD and LDL-C of 115-190 m~dl to fiuvastatin (FL) 20 mg bid or placebo
(PL); adjunctive cholestyrsmine was given when prerandomization LDL-C
remained ?160 (25% of pts). Among the 340 pts evaluable for angiogrephy,
baseline mean (+ SD) lipid values for FL vs PL were HDL-C 43.4 + 11.7
vs 44.9 + 12.6 m~dl, LDL-C 145.9 * 19.9 vs 144.1 + 19.6 mg/dl. HDL-C
was 45 mgldl in 42 FL (zs~o) and 26 PL (17%) pts. CAD progression
wassignificantly greater in these 70 Iow-HDL pts than in pts with HDL-C
>35 mg/dl: change in minimum lumen diameter (mean * SEM) –0.156 Z+
0.026 vs –0.054 + 0.016 mm (p < 0.001). Among Iow-HDL pts, fluvastatin
treatment significantly reduced progression compared with PL: –0.073 +
0.037 vs –0.239 + 0.042 mm (p = 0.003). Conclusion: Patients with HDL-C
<35 m@dland mildly elevated LDL-C had more rapid progression of CAD,
which was significantly slowed by treatment with FL, an agent that primarily
influences LDL-C.
D96932 ImprovementofAtherosclerosisof thaThoracicDescending Aorte by Cholesterol Lowering
Therapies in Patiente with Hyperlipidemia
Y.Tomochika, N. Tanaka, S. One, K. Murete, T. Tone, A. Muro,
M. Matsuzaki. Yamaguchi University Uba, 755, Japan
Toasaessthe regression of atherosclerosis by cholesterol lowering therapies
(CLT), we evaluated atheromatous lesions (AL) and stiffness of the thoracic
descending aorta (DAo) in 16 familial hypercholesterolemia (FH), 15 non-FH
hyperlipidemic patients (non-FH) and 17 age-matched normal subjects (N)
with trensesophageal echography (TEE). Total atheromatous score (TAS), a
quantitative index of severity of AL was obtained by 2-D TEE (Arteriosc/er
Thromb Vase Bio/. August 1996). TAS was significantly higher in FH than
non-FH or N. We also calculated stiffness parameter (fJ;= In (Pa/Pd)/(Dmax
- Dmin/Dmin), Ps: systolic blood pressure, Pd: diastolic P,Dmex and Dmin:
maximum and minimum DAo diameter) using M-mcde TEE. ~ in FH and
non-FH were higher than N. In both FH and non-FH, TAS correlated with
total cholesterol levels (TC; r= O.64,p <0.01, r= O.58,p c 0.05, respectively)
before CLT. There were significant correlations between age and p in all 3
groups (FH; r= 0.67, p <0.005, non-FH; r= 0.53, p <0.05, N; r = 0.49, p <
0.05), however, the slopes of regression lines of FH and non-FH were much
steeper than N. In FH and non-FH, CLT (FH; probucol and pravastatin, non-
FH; simvastatin) were undertaken for 15 months. In both FH and non-FH,
TC was significantly decreased (333+45-+213+42 mg/dl, 266 +27-+212
+ 17, respectively, both p < 0.0001), associated with significant decreases
in TAS (3.6 + 1.6+2.6 + 1.2, p <0.005, 2.4 + 0.7+2.0 & 4.3, p <0.01,
respectively) and o (10.0 + 5.0+7.9 + 3.9, p <0.01, 10.1 + 4.3+7.3 +
3.0, p <0.005, respectively). Although correlation between age and B was
presemd during CLT in FH, the slope of regression line during CLT became
more shallow than that at baseline. These results suggest that CLT could
not only regress atherosclerotic lesions but also modify progression of aortic
sclerosis with age even in FH. Thus, TEE might be feasible method to monitor
the effect of treatment on atherosclerosis durfng CLT.
D96933 Effect of Six-Month Antilipemic Therapy on
Coronsry Leeions and Clinicsl Eventa in Patients
With Coronary Heart Disease
H.-R. Arntz, T. Linderer, W. Wunderlich, L. Schnitzer, R. Stern, R. Agrewal,
S.N. Willich, H.-P.Schultheiss. Benjamin Franklin Mad Centefi Berlin,
Germany
Inaprospsctive randomized controlled trial of pts with coronary heart dieease
and moderate hypercholesterolemia (LDL-Chol ? 160s 250 mg/dl), maximal
antilipamic therapy (MAX) was compared with conventional therapy (CON).
MAX consisted of pravastatin (P) 40 mg daily and stepwise addition of
mlestyramine (C) and nicotinic acid (N) to achieve an LDL-Chol <130 mg/dl.
CON was administered at the discretion of the private physician. After 6
months changes in minimal lumen diameter (MLD) and % diameter stenosis
(%DS) were quantified from repeat coronary angiography (analytic isocanter
calibration method) in up to 9 prospectively defined lesions per patient.
Results: Of 126 pts, 56 were randomized to CON (age 56 + 10, 79% male),
70 to MAX (age 55 + 9, 61% male). At inclusion total cholesterol was 236 +
27 mg/dl for MAX pts and 234+29 mg/dl for CON pts, LDL-Chol 176+26
mg/dl and 177+ 30 mg/dl, respectively. Of the MAX pts 56 received P only,
11 P + C, 1 P + C + N. Of CON, 9 pts received at least one antilipemic agent.
Total cholesterol wee reduced by 21%, LDL-Chol by 30% with MAX, whereas
both values remained aimilar with CON (differences p < 0.001). Average
MLD par patient increased byO.03 + 0.2 mm with MAX, whereas with CON it
decreased by 0.06+ 0.2 mm (p= 0.1). Average% DS decreased by 1 +6%
with MAX, but increased by2 + 5%.with CON (p= 0.01). A per lesion analysis
revealad more pronounced differences in favour of MAX for MLD and % DS
(p= 0.006). Regression only (increase of MLD >0.15 mm) was seen in 26%
of the pts with MAX and in 12% with CON (p = 0.02). Clinical events (death,
AMI, angioplasty, bypass surgery) tended to occur less frequently with MAX
compared to CON (7 events with MAX, 12 with CON).
Conclusions: Vigorous cholesterol reduction decreases progression and
induces regression of coronary lesions already within 6 months of therapy,
and is associated with a trend towards fewer clinical events.
]969-34]LipOprOtein(a)DOeS NOtCOrre,ate with Early
Atherosclaroais as Seen on Intracoronary
Ultrasound in Asymptomatic Familial
Hyperlipidamia
T.M. Chou, J.C. Messenger, J. Naya-Vigne, A. Durairaj, E. Ko, C.A. Zellner,
K. Sudhir, M.J. Malloy; J.P. Kane. Univaraity of California, San Francisco,
CA, USA
Elevated Lipoprotein (a) (Lp(a)) has been found to be associated with coro-
nary artery disease and ischemic events. We correlated Lp(a) concentrations
in asymptomatic patients with familial hypercholesteroiemia and familial com-
bined hyperlipidemia with intravascular ultrasound (IVUS) indices of coronary
artery disease. Theleftmain (LM) and proximal Ieftanteriordescending (LAD)
coronary arteries in 61 subjects (34 males: 45 + 2 years, 25 females: 50
+ 2 years) were imaged using mechanical 1 mrnlsec timed IVUS pullbacks
from the LAD to LM. IVUS images were analyzed using specialized software.
Lipoprotein fractions were separated ultracentrifugally. Lp(a) was quantified
immunochemically as Lp(a)-associated apolipoprotein B. There was no sta-
tistically significant difference in mean Lp(a) between males and females
(176 +38 and 130 +26 nM/L, p = 0.30). Lp(a) was inversely correlated with
VLDL cholesterol (r = –0.35) but did not correlate with total, LDL or HDL
cholesterol. Lp(a) did not correlate with any of seven IVUS indices of plaque
(average intimal area, % disease area, average intimal thickness, % disease
slices, average calcium arc present, % calcium slicea, intimal index). We
conclude that in asymptomatic patients with primary hyperlipidemia, Lp(a) is
not predictive of coronary artery disease as assessed by IVUS. This suggests
that Lp(a) is not involved the early growth of plaque. Rather, Lp(a) may be
associated with other factors that relate to plaque stability.
\969-351 Joint Effects of Triglycerides and Lipoprotein
Cholesterol on CHD Deaths: PoI-MONICA Waraaw
Follow-up Program
G. Broda, S. Rywik, D. Szczesniewska. National institute of Cardiology
Warsaw,Poland
Combined effects of baseline triglycerides (TG) and lipoprotein cholesterol
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n970 Unstable Angina: Plasma Markers
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